Ney Carter Borges: New Trial Highlights IVL as Effective Strategy for Calcified Coronary Lesions
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn about a recent article by Benjamin Honton et al, published in EuroIntervention, adding:
“ICARE OFDI was a multicenter, prospective, randomized non-inferiority trial comparing intravascular lithotripsy (IVL) with rotational atherectomy (RA) for preparation of moderate-to-severe calcified coronary lesions before PCI.
All procedures were guided by optical frequency domain imaging.
In 169 patients:
- RA n=86
- IVL n=83
IVL was non-inferior to RA for the primary imaging endpoint, minimal stent area: 6.0 plus/minus 2.3 square millimeter versus 5.9 plus/minus 2.2 square millimeter, respectively.
Adequate stent expansion was identical in both groups, 65.1 percent versus 65.1 percent, while major strut malapposition was significantly more frequent after RA: 80.2 percent versus 57.8 percent; p=0.002.
Clinically, both strategies had similar procedural safety and very low 12-month target lesion failure: RA 1.2 percent versus IVL 2.4 percent; p=0.61.
Clinical interpretation: IVL appears to be a valid alternative to RA for stable calcified coronary lesions, offering comparable stent expansion and outcomes, with less major malapposition.
However, the trial was relatively small and powered for an imaging endpoint, not hard clinical outcomes.
Larger trials are still needed before declaring IVL superior.”
Title: Intravascular lithotripsy in comparison to rotational atherectomy for calcified lesions: the ICARE OFDI randomised trial
Authors: Benjamin Honton, Pascal Motreff, Jean-Sébastien Mallet, Thomas Hovasse, Matthieu Godin, Guilhem Malclès, Jerome Brunet, Nicolas Meneveau, Pierre Deharo, Benoit Lattuca, Erwan Bressollette, Michael Angioi, Hakim Benamer, Edouard Gerbaud, Bruno Pereira, Vincenzo Cesario, Antoine Poinas, Clémence Laperche, Antoine Sauguet, Géraud Souteyrand, Nicolas Amabile, Nicolas Combaret

Other posts featuring Ney Carter Borges on Hemostasis Today.
-
May 22, 2026, 13:36Ajay Samkaria։ A Compatible Crossmatch Does Not Always Mean Complete Safety
-
May 22, 2026, 13:31Mariam Swidan: Why Hemolysis Severity Matters in G6PD Deficiency
-
May 22, 2026, 13:25Augustina Isioma Ikusemoro: Why Plasma and RBC Transfusions Follow Different Compatibility Rules
-
May 22, 2026, 13:08Anas Hamad: Thrombosis as Overlooked Clinical Challenge in APL
-
May 22, 2026, 12:29Neema Ngugi: Highlighting 6 Major Types of Anemia
-
May 22, 2026, 12:27Jacinto López Sagaseta: Solving the Structural Puzzle of FVIIa–EPCR Interaction
-
May 22, 2026, 12:25Shehab Mohamed: Exploring the Emerging Link Between JAK2 Mutations and Thoracic Aortic Aneurysms
-
May 22, 2026, 11:52Prakash W. Kamat: Highlighting the Role of Physical Activity in Hemophilia Management
-
May 22, 2026, 11:43Mohamed Hanafy Morsy: Understanding Hemochromatosis – Genetics Made Simple